Amendments To The Claims

This listing of claims will replace all prior versions of claims in the application.

- 1. (Currently Amended) A method of reducing breast density, comprising percutaneously administering, to a patient having class III or class IV dense breast composition, a pharmaceutical composition for percutaneous administration comprising 4-hydroxy tamoxifen and isopropyl myristate percutaneously to a patient having class III or class IV dense breast composition.
- 2. (Original) A method according to claim 1, wherein said dense breast tissue is diffuse.
- 3. (Original) A method according to claim 1, wherein said dense breast tissue is nodular.
- 4. (Canceled)
- 5. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a racemic blend of *trans* and *cis* isomers.
- 6. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a *trans* isomer.
- 7. (Original) A method according to claim 1, wherein greater than about 0.5 mg/breast of said 4-hydroxy tamoxifen is administered per day.
- 8. (Original) A method according to claim 1, wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen is administered per day.
- 9. (Original) A method according to claim 1, wherein greater than about 1.0 mg/breast of said 4-hydroxy tamoxifen is administered per day.
- 10. (Currently Amended) A method according to claim 1, wherein said 4-hydroxy tamoxifen is formulated in pharmaceutical composition comprises a hydroalcoholic gel.
- 11. (Original) A method according to claim 10, wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.

- 12. (Currently Amended) A method according to claim 1, wherein said 4-hydroxy tamoxifen is formulated in pharmaceutical composition comprises an alcoholic solution.
- 13. (Withdrawn Currently Amended) A method of diagnosing breast disease[[, comprising]] that comprises performing the method of claim 1, then performing mammography on [[a]] said patient having dense breast composition, wherein said patient has been percutaneously administered 4 dydroxy tamoxifen.
- 14. (Canceled)
- 15. (Withdrawn) A method according to claim 13, wherein said 4-hydroxy tamoxifen is a racemic blend of *trans* and *cis* isomers.
- 16. (Withdrawn) A method according to claim 13, wherein said 4-hydroxy tamoxifen is a *trans* isomer.
- 17. (Withdrawn) A method according to claim 13, wherein greater than about 0.5 mg/breast of said 4-hydroxy tamoxifen has been administered per day.
- 18. (Withdrawn) A method according to claim 13, wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen has been administered per day.
- 19. (Withdrawn) A method according to claim 13, wherein greater than about 1.0 mg/breast of said 4-hydroxy tamoxifen has been administered per day.
- (Withdrawn Currently Amended) A method according to claim 13, wherein said 4hydroxy tamoxifen is formulated in pharmaceutical composition comprises a hydroalcoholic gel.
- 21. (Withdrawn) A method according to claim 20, wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.
- 22. (Canceled)

- 23. (New) A method according to claim 10, wherein said pharmaceutical_composition comprises 4-hydroxy tamoxifen, ethyl alcohol, isopropyl myristate, hydroxymethylcellulose and phosphate buffer.
- 24. (New) A method according to claim 10, wherein said pharmaceutical composition comprises from about 0.001 g to about 1.0 g of 4-hydroxy tamoxifen per 100 g gel.
- 25. (New) A method according to claim 24, wherein said pharmaceutical_composition comprises from about 0.01 g to about 0.1 g of 4-hydroxy tamoxifen per 100 g gel.
- 26. (New) A method according to claim 20, wherein said pharmaceutical composition comprises 4-hydroxy tamoxifen, ethyl alcohol, isopropyl myristate, hydroxymethylcellulose and phosphate buffer.
- 27. (New) A method according to claim 20, wherein said pharmaceutical composition comprises from about 0.001 g to about 1.0 g of 4-hydroxy tamoxifen per 100 g gel.
- 28. (New) A method according to claim 27, wherein said pharmaceutical composition comprises from about 0.01 g to about 0.1 g of 4-hydroxy tamoxifen per 100 g gel.